The Endocrine Society has officially submitted a comprehensive set of comments to the Centers for Medicare and Medicaid Services regarding the proposed rule for the Calendar Year Medicare Physician Fee Schedule. This annual regulatory update, which dictates the payment policies and rates for Part B services, remains one of the most critical windows for medical specialty societies to influence the federal government’s healthcare spending priorities. In its latest communication, the Endocrine Society addressed a complex landscape of proposed financial adjustments, coding revisions, and administrative shifts that could fundamentally alter the economic stability of endocrinology practices across the United States. While the proposed rule includes some favorable updates for specific procedures, it also introduces significant concerns regarding the overall conversion factor and the restructuring of complexity-based coding.
The Economic Context of the Proposed Rule
The Medicare Physician Fee Schedule is governed by a statutory requirement for budget neutrality. This means that if CMS increases payment for certain services or specialties, it must offset those increases by decreasing payments elsewhere to ensure the total spend does not exceed a predetermined threshold. For the upcoming calendar year, the proposed rule indicates a 2.5% increase in reimbursement specifically for the endocrinology specialty. However, this localized gain is overshadowed by a broader fiscal reality: a proposed 2.5% overall decrease to the conversion factor for all physicians.
The conversion factor is the dollar amount multiplied by the Relative Value Units assigned to a service to determine the final payment. A decrease in this factor effectively functions as a pay cut for all Medicare-participating physicians, regardless of their specialty’s individual standing. The Endocrine Society, alongside a broad coalition of medical organizations including the American Medical Association, has argued that the current system is unsustainable. While the Medicare Economic Index—a measure of the inflation in the cost of practicing medicine—continues to rise, physician reimbursement has failed to keep pace. The Society is currently urging Congress to intervene by passing legislation that provides an annual inflationary update tied to the MEI, which would override the CMS-mandated cuts and provide long-term stability for the healthcare workforce.
Technical Wins in Procedural Reimbursement: Fine Needle Aspiration
A significant portion of the Endocrine Society’s comments focused on specific procedural inputs that affect the daily practice of endocrinologists, particularly those specializing in thyroid care. The Society expressed strong support for the CMS proposal to create a new practice expense equipment item for Fine Needle Aspiration services. The proposed item, designated as ER130 ("Fine Needle Aspiration portable ultrasound"), represents a major advocacy victory for the organization.
For years, the Endocrine Society worked in tandem with other medical societies through the Current Procedural Terminology (CPT) and the RUC (Relative Value Scale Update Committee) process to demonstrate that the costs associated with performing FNAs had been undervalued. By formally recognizing the portable ultrasound as a distinct practice expense input, CMS is acknowledging the technological requirements of modern endocrine procedures. This update is expected to more accurately reflect the overhead costs incurred by specialists, ensuring that clinicians can continue to offer high-quality diagnostic services in an office-based setting rather than referring patients to more expensive hospital environments.
The G2211 Controversy and the Shift to MOD1
One of the most contentious points in the Endocrine Society’s letter involves the proposed deletion of the G2211 complex care code. Only recently implemented, G2211 was designed to account for the additional work and resources required to manage patients with complex, chronic conditions—a cornerstone of endocrinology. CMS has now proposed replacing this code with a new modifier, currently referred to as MOD1.
Under the new proposal, the MOD1 modifier would be appended to an appropriate Evaluation and Management (E/M) code, resulting in a payment increase equal to 16% of the value of the reported E/M CPT code. While this might appear to be a streamlining of the billing process, the Endocrine Society has expressed deep concern regarding its impact on Work Relative Value Units (wRVUs). The Society’s analysis suggests that the transition from a standalone code to a percentage-based modifier would result in a net loss of wRVUs for many physicians, particularly those operating within large hospital systems and academic universities.
In these larger systems, physician compensation and productivity metrics are often tied directly to wRVU targets. A reduction in the wRVU value of complex care visits could lead to decreased compensation for specialists who manage the most difficult patient populations, such as those with brittle diabetes, rare adrenal disorders, or thyroid malignancies. The Endocrine Society has formally urged CMS not to finalize this proposal, advocating instead for the retention of the G2211 code to ensure that the inherent "work" of managing complexity is fully captured and compensated.
Modifier 25 and the Bundling of Services
The Society also addressed a proposal that would reduce payment when using Modifier 25 under certain circumstances during an E/M visit. Modifier 25 is used to indicate that on the day a procedure or service was performed, the patient’s condition required a significant, separately identifiable E/M service above and beyond the other service provided.
Endocrinologists frequently utilize Modifier 25 when they see a patient for a routine follow-up and discover a new, urgent issue that requires immediate attention or a minor procedure. CMS’s proposal to reduce payment for these bundled services is seen by the Society as a deterrent to efficient care. If reimbursement is cut for providing multiple services in a single visit, physicians may be forced to schedule separate appointments, increasing the burden on patients—particularly those in rural areas or with mobility issues—and ultimately increasing the total cost to the Medicare system through multiple facility fees and administrative overhead.
Chronology of Advocacy and Rulemaking
The development of the Endocrine Society’s response was a multi-month effort involving rigorous data analysis and expert consultation. The process followed a specific timeline:
- July: CMS released the initial Physician Fee Schedule proposed rule, initiating a 60-day public comment period.
- August: The Endocrine Society staff began collaborating with the Clinical Affairs Core Committee (CACC) to analyze the 2,000-page document and identify the provisions most impactful to the specialty.
- Late August: Feedback was solicited from the broader membership to understand how changes to G2211 and the conversion factor would affect different practice models, from independent clinics to large academic medical centers.
- September 11: The Society officially submitted its formal comment letter to CMS, outlining its support for the FNA updates and its opposition to the G2211 deletion and Modifier 25 reductions.
- November (Expected): CMS is scheduled to release the Final Rule, which will take effect on January 1 of the following year.
Broader Implications for the Medical Field
The challenges faced by the Endocrine Society are reflective of a broader crisis in the American healthcare system. The persistent threat of Medicare cuts, combined with the administrative burden of new coding requirements, has contributed to a rise in physician burnout and a decrease in the number of specialists participating in the Medicare program.
According to data from the Medicare Trustees, while the cost of living and the cost of running a practice have surged by over 20% in the last two decades, inflation-adjusted physician payment has actually declined. This disparity is particularly acute for "cognitive" specialties like endocrinology, which rely heavily on E/M codes rather than high-volume surgical procedures. The Society’s push for an MEI-based update is not merely a request for higher pay, but a demand for a sustainable economic framework that allows physicians to keep their doors open to the aging Medicare population.
Furthermore, the debate over G2211 and the MOD1 modifier highlights the ongoing tension between "simplification" and "accuracy" in medical billing. While CMS often seeks to simplify the fee schedule to reduce errors and administrative costs, the Endocrine Society argues that such simplification must not come at the expense of recognizing the specialized labor required to manage chronic disease.
Conclusion and Next Steps
As the healthcare community awaits the final rule from CMS in early November, the Endocrine Society remains active in its advocacy efforts on Capitol Hill. The organization continues to emphasize that while regulatory comments are essential, the ultimate solution to the "Medicare cliff" lies in the hands of Congress. By advocating for a stable, inflationary update to the conversion factor, the Society aims to move away from the annual cycle of proposed cuts and last-minute legislative "fixes" that have characterized Medicare policy for the last decade.
The Society’s collaboration with the Clinical Affairs Core Committee underscores the importance of physician-led advocacy. By grounding their arguments in clinical reality and practice-level data, the Endocrine Society provides CMS with a clear picture of how abstract policy changes translate into real-world patient care. For now, endocrinologists are encouraged to review the full text of the Society’s letter and prepare for the potential shifts in billing and reimbursement that will define the upcoming clinical year. The final outcome of these negotiations will determine not only the financial health of the specialty but also the accessibility of specialized care for millions of Medicare beneficiaries across the country.
